Comorbidities and their impact on chronic obstructive pulmonary disease
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Open Access Color
GOLD
Green Open Access
Yes
OpenAIRE Downloads
OpenAIRE Views
Publicly Funded
No
Abstract
Chronic obstructive pulmonary disease (COPD) is a complex disease that is associated with devastating outcomes resulting from lung involvement and several comorbidities. Comorbidities could impact on symptomology, quality of life, the complications, the management, economic burden and the mortality of the disease. The importance of comorbidities originates from their impact on the outcome of COPD. The most frequent comorbidities in COPD are cardiovascular, endocrinological, musculoskeletal, phycological disorders and lung cancer. Almost 50% of the COPD patients have 3 or more comorbidities. The recent Global Initiative of Obstructive Lung Disease (GOLD) Guideline suggested proactive search and the treatment of the comorbidities. However, there is no certain evidence demonstrating that active treatment of comorbidities improve the outcomes of COPD. However, it is well known that several comorbidities such as cardiovascular disease and lung cancer have greater impact on mortality caused by COPD. Several studies have shown that Charlson Comorbidity index or more recenty COPD Specific Comorbidity Index (COTE) has been found to be related with mortality of COPD. This concise review intended to summarize the most frequent comorbidities in association with their impact on COPD. © 2016, Ankara University. All rights reserved.
Description
ORCID
Keywords
Comorbidity, COPD, C reactive protein, calcium, denosumab, fibrinogen, ghrelin, growth hormone, interleukin 1beta, interleukin 6, megestrol, parathyroid hormone[1-34], testosterone, tumor necrosis factor, vitamin D, aging, anemia, anxiety, Article, asthma, body mass, chronic obstructive lung disease, clinical trial (topic), comorbidity, depression, diabetes mellitus, emphysema, family history, gastroesophageal reflux, heart failure, human, hypertension, ischemic heart disease, lung cancer, lung diffusion capacity, lung fibrosis, malnutrition, metabolic syndrome X, musculoskeletal disease, obesity, osteoporosis, respiratory system, sleep disorder, smoking, vitamin D deficiency, Cardiovascular Diseases, disease management, health status, Lung Neoplasms, Musculoskeletal Diseases, Pulmonary Disease, Chronic Obstructive, quality of life, cardiovascular disease, complication, lung tumor, Diabetes Mellitus, Disease Management, Health Status, Humans, Quality of Life, obesity, interleukin 1beta, Lung Neoplasms, Health Status, gastroesophageal reflux, heart failure, vitamin D, health status, Comorbidity, lung tumor, Pulmonary Disease, Chronic Obstructive, cardiovascular disease, Musculoskeletal Diseases, megestrol, sleep disorder, family history, C reactive protein, Disease Management, clinical trial (topic), anxiety, anemia, comorbidity, emphysema, Cardiovascular Diseases, ghrelin, depression, diabetes mellitus, parathyroid hormone[1-34], lung diffusion capacity, hypertension, tumor necrosis factor, vitamin D deficiency, interleukin 6, complication, malnutrition, Article, smoking, 616, Diabetes Mellitus, COPD, Humans, human, calcium, aging, lung fibrosis, denosumab, asthma, ischemic heart disease, osteoporosis, body mass, respiratory system, lung cancer, disease management, quality of life, growth hormone, testosterone, Quality of Life, fibrinogen, metabolic syndrome X, chronic obstructive lung disease, musculoskeletal disease
Fields of Science
0302 clinical medicine, 03 medical and health sciences
Citation
WoS Q
Scopus Q

OpenCitations Citation Count
11
Source
Volume
64
Issue
4
Start Page
289
End Page
298
PlumX Metrics
Citations
CrossRef : 8
Scopus : 8
Captures
Mendeley Readers : 65
SCOPUS™ Citations
8
checked on Jun 06, 2026
Web of Science™ Citations
9
checked on Jun 06, 2026
Page Views
58
checked on Jun 06, 2026
Downloads
30
checked on Jun 06, 2026
Google Scholar™



